This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (673) Web-based and Mobile Health Interventions (4042) Digital Mental Health Interventions, e-Mental Health and Cyberpsychology (2132) mHealth for Treatment Adherence (471) Depression and Mood Disorders; Suicide Prevention (1702) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1743)

Published on in Vol 13 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56960, first published .
Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

Authors of this article:

Brian Rothman1 Author Orcid Image ;   Mary Slomkowski1 Author Orcid Image ;   Austin Speier2 Author Orcid Image ;   A John Rush3, 4 Author Orcid Image ;   Madhukar H Trivedi5, 6 Author Orcid Image ;   Erica Lawson1 Author Orcid Image ;   Michael Fahmy1 Author Orcid Image ;   Daniel Carpenter7 Author Orcid Image ;   Dalei Chen1 Author Orcid Image ;   Ainslie Forbes1 Author Orcid Image
Article Authors Cited by (6) Tweetations Metrics

Journals

  1. Zovi A, Ferrara F, Gelmi M, Messina N, Pagani A, Patti T, Zanetti Lorenzetti E, Torri T, Langella R. Digital therapeutics as a new weapon against diseases: focus on the current European legislation and possible therapeutic strategies. Expert Review of Medical Devices 2025;22(2):141 View
  2. Rothman B, Slomkowski M, Speier A, Rush A, Trivedi M, Lakhan S, Lawson E, Fahmy M, Carpenter D, Chen D, Docherty J, Forbes A. A digital therapeutic (CT-152) as adjunct to antidepressant medication: A phase 3 randomized controlled trial (the Mirai study). Journal of Affective Disorders 2025;388:119409 View
  3. Koller C, Blanchard M, Hügle T, Or C. Assessment of digital therapeutics in decentralized clinical trials: A scoping review. PLOS Digital Health 2025;4(6):e0000905 View
  4. Vaishnavi S, Leow A, Nguyen V, Meyer C, Keleher M, Leitschuh C, Carlton T. Changes in Neural Activities and Neuroplasticity Related to Nonpharmacological Interventions for Major Depressive Disorder: A Systematic Literature Review. Biological Psychiatry Global Open Science 2025;5(6):100572 View
  5. Wang H, Daizadeh N, Shen Y, Chen J, Rockhold F, Pang H, Lee H. Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences. Clinical and Translational Science 2025;18(9) View
  6. Lakhan S, Dorner-Ciossek C, Besedina O, Dickerson F, Hastedt C, Isla R, Kahn R, Lindenmayer J, Mehta R, Snipes C, Speier A, Tang W, Willis B, Fernandez J, von der Goltz C, Pratap A. Effectiveness, Engagement, and Safety of a Digital Therapeutic (CT-155/BI 3972080) for Treating Negative Symptoms in People With Schizophrenia: Protocol for the Phase 3 CONVOKE Randomized Controlled Trial. JMIR Research Protocols 2025;14:e81293 View